www.fdanews.com/articles/157303-genentech-s-obinutuzumab-delayed-disease-progression-longer-than-rituxan
Genentech’s Obinutuzumab Delayed Disease Progression Longer Than Rituxan
July 24, 2013
Genentech announced encouraging results from its Phase III CLL11 study that showed that its obinutuzumab plus chlorambucil combination delayed the progression of chronic lymphocytic leukemia longer than rituxan.
Genentech
Genentech